Stanford Study: Ibogaine Reduces PTSD Symptoms by 88% in Veterans
A groundbreaking study published in Nature Medicine by researchers at Stanford University has demonstrated an 88% reduction in PTSD symptoms among military veterans following ibogaine treatment.
Study Highlights
- 30 veterans participated in the controlled study over 12 months
- Single treatment session produced lasting results at 6-month follow-up
- Disability ratings decreased by an average of 60% among participants
- No serious adverse events reported under medical supervision
Methodology
The study used the Clinician-Administered PTSD Scale (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5) to measure outcomes. Veterans received ibogaine hydrochloride under continuous cardiac monitoring in a clinical setting.
Implications
This study represents the strongest clinical evidence to date for ibogaine's efficacy in treating PTSD. The results are particularly significant given that many participants had been classified as "treatment-resistant" after failing multiple rounds of conventional therapy.
Dr. Nolan Williams, the study's lead researcher, noted: "These results suggest ibogaine could fundamentally change how we approach treatment-resistant PTSD."
Related Articles
Ibogaine Research in 2026: What the Evidence Actually Shows
A plain-language review of the ibogaine research landscape — mechanistic findings, observational outcome data, the Stanford veterans study, active clinical trials, and the significant gaps that remain unfilled.
ResearchIbogaine Relapse Rates: Why No One Can Honestly Quote You a Number
Clinics quote ibogaine relapse statistics with striking confidence. The registered research base is roughly 145 people across three completed trials — none of them in the United States. Here is what the evidence supports, what it does not, and what actually predicts relapse.
ResearchIbogaine Research in 2026: What the Science Actually Shows
A clear-eyed review of ibogaine research: Stanford's landmark TBI study, opioid detox outcomes, state-funded clinical trials, mechanisms of action, and the honest limits of the current evidence.